Multidomain lifestyle interventions combined with pharmacological or nutraceutical approaches may improve cognition in individuals across the Alzheimer's disease continuum.
A systematic review of 12 randomized controlled trials found that combining multidomain lifestyle interventions (2-7 domains including physical exercise, cognitive training, dietary guidance, social activities, sleep hygiene, cardiovascular/metabolic risk management, psychoeducation or stress management) with pharmacological components (e.g., Omega-3, Tramiprosate, vitamin D, BBH-1001, epigallocatechin gallate, Souvenaid, metformin) may effectively improve cognition. Seven trials targeted participants with prodromal AD, MCI, or early dementia, while five focused on at-risk individuals or those with subjective cognitive decline, with two studies enriching populations for APOE-ε4 carriers.
Evidence Score
Study Evidence
Study 1. Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches.
observationalBereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M · The journal of prevention of Alzheimer's disease (2025)
Result:
Mechanism Graph
Limitations
- ⚠Only 12 RCTs were identified, limiting generalizability
- ⚠Further refinement of RCT methodology is needed to better align with the multifaceted nature of dementia prevention
Frequently Asked Questions
What types of lifestyle domains were included in the interventions?▼
The interventions included 2 to 7 lifestyle domains such as physical exercise, cognitive training, dietary guidance, social activities, sleep hygiene, cardiovascular/metabolic risk management, and psychoeducation or stress management.
Which pharmacological components were combined with lifestyle interventions?▼
Pharmacological components included Omega-3, Tramiprosate, vitamin D, BBH-1001, epigallocatechin gallate, Souvenaid, and metformin.
Who was the target population for these combination trials?▼
The target population included individuals across the Alzheimer's disease continuum: cognitively normal at-risk individuals, those with subjective cognitive decline, mild cognitive impairment, or prodromal AD.
What was the minimum duration of the interventions in the reviewed trials?▼
All included interventions lasted at least 6 months.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M. "Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches.." The journal of prevention of Alzheimer's disease, 2025. PMID: 41145344 DOI: 10.1016/j.tjpad.2025.100367